SGLT2 drugs and heart artery health in diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have type 2 diabetes with moderate-to-high heart disease risk (SCORE2-Diabetes score above 10%)
- You have stable chest pain (angina) and narrowing in at least one heart artery (50–90% blockage)
- Your kidneys function reasonably well (eGFR of 45 or higher)
- You have not had heart surgery, stent placement, or a pacemaker implanted
- Your diabetes and heart medications have been stable for at least 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This study uses a follow-up CT scan of your heart arteries to see how diabetes-related plaque buildup changes over time. It may help researchers understand how well current diabetes treatments are protecting your heart.
This trial tests a screening and intervention approach for “silent” coronary artery disease (heart artery narrowing without major symptoms) in people with type 2 diabetes. It may help prevent future heart problems by finding higher-risk cases early and starting the right treatment plan.
This study tests a type of diabetes medicine (an SGLT2 inhibitor) to see if it helps improve heart function in people with type 2 diabetes. It specifically looks at changes in the left atrium, a chamber of the heart, and may help protect your heart over time.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.